Clinical trial · Observational
Detection of Chemotherapy Induced Cardiotoxicity
NCT00636844CI-TRIAL-00009710completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Group A
- description
- Patients receiving chemotherapy (anthracycline and/or adjuvant trastuzumab) for the first time
Primary outcomes (1)
- measure
- The genetic profile of patients with anthracycline-induced elevation of troponin-I
- timeFrame
- one year
Secondary outcomes (2)
- measure
- Assess the genetic profile of patient with anthracycline-induced left ventricular systolic and diastolic dysfunction
- timeFrame
- one year
- measure
- Assess the relationship of quantitative increases of pro-oxidant stress and a specific genetic profile
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * undergoing anthracycline and/or trastuzumab therapy for the first time Exclusion Criteria: * abnormal ventricular ejection fraction * past history of, or active cardiac disease including: MI, CHF, angina, arrhythmia requiring medication, valvular disease, uncontrolled systemic hypertension
References
Publications (0)
Data not yet available
No reference posted for this study.